Speech-Language Pathologists in Shelby, MS Accepting Medicare
2 Speech-Language Pathologists found. Showing 1 - 2
 Mrs. Louise H. Hemingway, MCD, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1902 Broadway Street, Shelby, MS 38774 Phone: 662-398-5065 Fax: 662-398-5065 |
Mrs. Sherica Anshon Willilams-reed, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 405 East Third Ave, Shelby, MS 38774 Phone: 662-398-9559 |
News Archive
Medicare buy-in option: Alternative approach to achieve wider access to care
Medicare-for-all, a solution that would bring United States healthcare policies more in line with other industrial nations, faces strong opposition and is unlikely to be enacted in the foreseeable future.
Researchers identify cells responsible for cardiac damage repair after infarction
Researchers at Cima and the Clinica Universidad de Navarra (Spain) have led an international study identifying the cardiac cells responsible for repairing the damage to this organ after infarction.
Fast Track designation for Terlipressin in type 1 hepatorenal syndrome
Protein Design Labs, Inc. and privately held Orphan Therapeutics, LLC today reported that the U.S. Food and Drug Administration (FDA) has granted Fast Track status to the development of terlipressin for the treatment of patients with type 1 hepatorenal syndrome (HRS).
Never too late to operate? Surgery near end of life is common, costly
At 87, Maxine Stanich cared more about improving the quality of her life than prolonging it. She suffered from a long list of health problems, including heart failure and chronic lung disease that could leave her gasping for breath.
Intellect Neurosciences receives patent for Alzheimer's disease monoclonal antibody program
Intellect Neurosciences, Inc., a biopharmaceutical company with internal preclinical and clinical-stage pipelines, as well as multiple licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has received a patent from the United States Patent and Trademark Office (USPTO) related to its internal Alzheimer's disease (AD) monoclonal antibody program.
› Verified 8 days ago